» Articles » PMID: 35497908

Appropriateness of Antifungal Prescribing in Oman

Overview
Date 2022 May 2
PMID 35497908
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The inappropriate use of antimicrobials has substantially contributed to the development of antimicrobial drug resistance. Appropriate antibacterial prescribing has been emphasised, with minimal focus on appropriate prescribing of antifungals. Evaluation of antifungal use in the clinical setting is essential to prevent unnecessary drug exposure, development of resistance, adverse effects, and high hospitalisation costs.

Objective: The purpose of this study was to assess the appropriateness of antifungal prescribing among adult patients at the Sultan Qaboos University Hospital (SQUH) in Oman.

Methods: In this retrospective, observational study, the study population comprised adult patients treated with oral or intravenous antifungals between July 2018 and December 2019. The appropriateness of treatment was assessed using guidelines from the Infectious Diseases Society of America (IDSA) and the National Comprehensive Cancer Network (NCCN), as well as a set of literature-based criteria that were modified by SQUH infectious diseases team to suit local practices. These criteria included indication, dosage, and potential drug interactions. The primary outcome was the frequency of adherence to the treatment guidelines for fungal infections. Descriptive statistics were used for data analysis.

Results: A total of 400 prescriptions were collected, of which 158 (39.5%) were for empirical therapy, 135 (33.8%) for targeted therapy, 69 (17.3%) for prophylactic therapy, and 38 (9.5%) for pre-emptive therapy. The overall appropriateness was 74.8%. The indication, dosage, and potential for antifungal-drug interactions were considered appropriate in 391 (97.8%), 314 (78.5%), and 381 (95.3%) prescriptions, respectively. Anidulafungin was the most prescribed antifungal agent, with 210 prescriptions (52.5%), followed by fluconazole with 102 prescriptions (25.5%), and voriconazole with 48 prescriptions (12%).

Conclusion: In comparison with publised literature, our study revealed appropriate antifungal drug prescribing practices. However, studies with larger sample size in various hospital settings are necessary to confirm our findings on a national scale, and to obtain better statistical inferences and generalisability.

Citing Articles

Antifungal Prophylaxis Utilization and the Associated Clinical Outcomes Among Pediatric Patients with Hematological Malignancies or Undergoing Hematopoietic Stem Cell Transplantation.

Al Siyabi B, Al-Maqbali J, Unnikrishnan Meenakshi D, Wali Y, Al Yazidi L J Clin Med. 2024; 13(23).

PMID: 39685638 PMC: 11642336. DOI: 10.3390/jcm13237179.


Evaluation of Systemic Antifungal Use in a Latin American General Care Hospital: A Retrospective Study.

Fallas-Mora A, Diaz-Madriz J, Chaverri-Fernandez J, Zavaleta-Monestel E Pharmacy (Basel). 2023; 11(4).

PMID: 37489339 PMC: 10366784. DOI: 10.3390/pharmacy11040108.


Study of Prescription-Indication of Outpatient Systemic Anti-Fungals in a Colombian Population. A Cross-Sectional Study.

Valladales-Restrepo L, Ospina-Cano J, Aristizabal-Carmona B, Lopez-Caicedo D, Toro-Londono M, Gaviria-Mendoza A Antibiotics (Basel). 2022; 11(12).

PMID: 36551462 PMC: 9774786. DOI: 10.3390/antibiotics11121805.

References
1.
Valerio M, Rodriguez-Gonzalez C, Munoz P, Caliz B, Sanjurjo M, Bouza E . Evaluation of antifungal use in a tertiary care institution: antifungal stewardship urgently needed. J Antimicrob Chemother. 2014; 69(7):1993-9. DOI: 10.1093/jac/dku053. View

2.
Poulat C, Nivoix Y, Launoy A, Lutun P, Bachellier P, Rohr S . Assessment of high-priced systemic antifungal prescriptions. Med Mal Infect. 2017; 47(6):382-388. DOI: 10.1016/j.medmal.2017.03.004. View

3.
Reboli A, Shorr A, Rotstein C, Pappas P, Kett D, Schlamm H . Anidulafungin compared with fluconazole for treatment of candidemia and other forms of invasive candidiasis caused by Candida albicans: a multivariate analysis of factors associated with improved outcome. BMC Infect Dis. 2011; 11:261. PMC: 3203347. DOI: 10.1186/1471-2334-11-261. View

4.
Ou H, Lee T, Chen Y, Charbonneau C . Pharmacoeconomic analysis of antifungal therapy for primary treatment of invasive candidiasis caused by Candida albicans and non-albicans Candida species. BMC Infect Dis. 2017; 17(1):481. PMC: 5504557. DOI: 10.1186/s12879-017-2573-8. View

5.
Hendrickson J, Hu C, Aitken S, Beyda N . Antifungal Resistance: a Concerning Trend for the Present and Future. Curr Infect Dis Rep. 2019; 21(12):47. DOI: 10.1007/s11908-019-0702-9. View